VirtualScopics third-quarter revenues increase 25% to $3.5 million

NewsGuard 100/100 Score

VirtualScopics, Inc. (Nasdaq: VSCP), a provider of quantitative imaging for clinical trials, today announced revenues for the third quarter ended September 30, 2010 exceeded $3.5 million, representing a greater than 25% increase over the comparable period in 2009 and a greater than 9% growth over the preceding quarter ended June 30, 2010. Year-to-date revenues increased over 30% for the period ended September 30, 2010 compared to the same period in 2009.

"We are extremely pleased to deliver another quarter of record revenue," stated Jeff Markin, president and chief executive officer of VirtualScopics. "Our growth this year has been spurred by the demand for our services within later stage clinical trials and as a result, our 2010 year-to-date clinical trial revenues have already exceeded what we recognized for the full year in 2009."  He added, "Our strong value proposition within the industry is one of the main contributors to our ability to report our 13th consecutive quarter of revenue growth." He concluded, "We are excited about our opportunities as we enter the fourth quarter and anticipate a solid close to 2010."

VirtualScopics plans to report its complete third quarter 2010 financial results on Thursday, November 11, 2010.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis